Physician profile
Yousong Wang
NPI 1023253200
$23,137.53
in general payments reported to CMS, 2019-2025
32 companies · $4,082 in 2025
The $4,082 reported for 2025 was more than what 98% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,028 · 2020: $2,277 · 2021: $2,433 · 2022: $2,937 · 2023: $3,751 · 2024: $3,629 · 2025: $4,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,073.53 |
| Education | $388.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,104.09 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $3,017.12 | 2019-2025 | Enbrel, Krystexxa, Otezla |
| Ucb, INC. | $2,679.08 | 2019-2025 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $2,357.39 | 2019-2023 | Krystexxa |
| Pfizer INC. | $1,718.13 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,347.70 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $1,338.11 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Astrazeneca Pharmaceuticals LP | $1,208.01 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $959.71 | 2019-2025 | Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $881.39 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $620.29 | 2019-2025 | Orencia, Sotyktu |
| Mallinckrodt Hospital Products INC. | $570.91 | 2020-2025 | Acthar |
| Genentech USA, INC. | $553.78 | 2019-2025 | Actemra, Gazyva |
| Actelion Pharmaceuticals US, INC. | $339.38 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Aurinia Pharma U.S., INC. | $296.10 | 2021-2024 | Lupkynis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $187.00 | 2019 | |
| Fresenius Kabi USA, LLC | $133.80 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.90 | 2019-2024 | Cyltezo, Ofev |
| Alexion Pharmaceuticals, INC. | $115.85 | 2019-2024 | Strensiq |
| Sandoz INC. | $92.73 | 2023-2024 | Hyrimoz |
| Organon LLC | $90.75 | 2022-2025 | Renflexis, Hadlima |
| Genzyme Corporation | $79.01 | 2023-2024 | |
| Hikma Pharmaceuticals USA | $53.25 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $52.16 | 2024 | Arcalyst |
| Scilex Pharmaceuticals INC. | $48.72 | 2024 | |
| Sobi, INC | $44.22 | 2019-2025 | |
| Celgene Corporation | $30.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.94 | 2024 | Hyqvia |
| Kiniksa Pharmaceuticals, LTD. | $20.38 | 2022 | |
| Radius Health, INC. | $19.97 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.50 | 2019 | |
| Merck Sharp & Dohme LLC | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yousong Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.